This trial is active, not recruiting.

Conditions non-small-cell lung cancer (nsclc), brain metastasis
Treatment hippocampal-sparing wbrt
Phase phase 2/phase 3
Sponsor Chang Gung Memorial Hospital
Start date August 2015
End date July 2018
Trial size 90 participants
Trial identifier NCT02448992, 103-6591A3


Background. During the clinical course of patients with locoregionally advanced non-small-cell lung cancer (LA-NSCLC) who have undergone aggressive treatment, brain metastasis (BM) is a frequent seen pattern of disease relapse, which cannot be ignored. It still remains unresolved whether prophylactic cranial irradiation (PCI) via whole brain radiotherapy (WBRT) should be recommended for NSCLC patients with stage III or pathologically nodal positive disease. Actually, PCI would significantly decrease the incidence of BM; however, potential WBRT-related neurocognitive function (NCF) sequelae are indeed a concern, which has made PCI seldom applied in clinical practice. In terms of the time course of WBRT-induced NCF decline, it might vary considerably according to the specific domains which are selected to be measured. Early neurocognitive decline principally involve impairments of episodic memory, which has been significantly associated with functions of the hippocampus. This study thus aims to explore the impact of PCI on the subsequent risk of developing BM and the multi-domain neurobehavioral functions in our eligible patients.

Methods. Potentially eligible subjects are postoperative NSCLC patients with a status of pathologically nodal metastasis (pN+). Patients randomly assigned to the PCI arm will undergo the course of hippocampal-sparing PCI after they complete the fourth course of adjuvant platinum-based chemotherapy. Radiotherapy dose will be 3000 cGy in 15 fractions during three weeks. Except for the administration of hippocampal-sparing PCI, patients assigned to the observation arm should receive the same baseline and follow-up brain imaging examinations and neurocognitive assessments as those in PCI arm. Accordingly, a battery of neuropsychological measures, which includes 7 standardized neuropsychological tests (e.g., executive functions, verbal & non-verbal memory, working memory, and psychomotor speed), is used to evaluate neurobehavioral functions for our registered patients.

Expected results. This randomized controlled study aims to verify that the incidence of BM still can significantly be reduced by hippocampal-sparing PCI; additionally, NCF preservation regarding neurobehavioral assessments might also be achieved by hippocampal-sparing PCI as compared with the observation arm without PCI. No matter what the final results present, it is believed that this randomized controlled trial (RCT) will provide us solid evidence concerning the exact value of hippocampal-sparing PCI in our patient setting.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking open label
Primary purpose treatment
All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25‐mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of WBRT, the technique of volumetric modulated arc therapy (VMAT) via Linac‐based RapidArc® or TrueBeamTM is employed in our treatment planning. All treatment plans are delivered by using the Linac Varian‐iX or TrueBeamTM. In terms of dose prescription, a dose of 30 Gy in 15 fractions is prescribed to whole‐brain planning target volume (PTV) under the setting of prophylactic cranial irradiation for NSCLC patients.
hippocampal-sparing wbrt
(No Intervention)

Primary Outcomes

time to the development of brain metastasis/metastases (BM), irrespective of the absence of active neurological symptoms
time frame: one year

Secondary Outcomes

the effects of hippocampal‐sparing PCI on neurocognitive functions (NCF)
time frame: up to 18 months

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: - Clinical diagnosis of NSCLC - Must be adult patients (≥ 18 years old) who have received definitive surgery and have a permanent pathology of nodal metastasis - Platinum‐based chemotherapy is mandatory - Good performance status better than Eastern Cooperative Group (ECOG) of 2 or a general status of Karnofsky (KPS) > 70 % - Should have sufficient proficiency in Mandarin language Exclusion Criteria: - Have received prior cranial irradiation - Presence of other active primary cancer (exception of basal cell carcinoma of skin and cervical carcinoma in situ) - Radiographic evidence of brain metastasis/metastases - Clinical evidence of extracranial metastatic disease - Hypersensitivity to magnetic resonance (MR) contrast enhancer - Serious medical or psychiatric illness

Additional Information

Official title Neuropsychological and Oncological Outcomes After Hippocampal-Sparing Prophylactic Cranial Irradiation in Postoperative Patients With Pathologically Nodal Positive Non-Small-Cell Lung Cancer - A Prospective Follow-up Study
Principal investigator Chi-Cheng Yang, Ph.D.
Trial information was received from ClinicalTrials.gov and was last updated in January 2016.
Information provided to ClinicalTrials.gov by Chang Gung Memorial Hospital.